741 related articles for article (PubMed ID: 33858437)
21. Personalized cancer vaccines: Targeting the cancer mutanome.
Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
[TBL] [Abstract][Full Text] [Related]
22. mRNA Cancer Vaccines-Messages that Prevail.
Grunwitz C; Kranz LM
Curr Top Microbiol Immunol; 2017; 405():145-164. PubMed ID: 28401358
[TBL] [Abstract][Full Text] [Related]
23. Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.
Chen YZ; Yao XL; Tabata Y; Nakagawa S; Gao JQ
Clin Dev Immunol; 2010; 2010():565643. PubMed ID: 21197274
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.
Tchou J; Zhao Y; Levine BL; Zhang PJ; Davis MM; Melenhorst JJ; Kulikovskaya I; Brennan AL; Liu X; Lacey SF; Posey AD; Williams AD; So A; Conejo-Garcia JR; Plesa G; Young RM; McGettigan S; Campbell J; Pierce RH; Matro JM; DeMichele AM; Clark AS; Cooper LJ; Schuchter LM; Vonderheide RH; June CH
Cancer Immunol Res; 2017 Dec; 5(12):1152-1161. PubMed ID: 29109077
[TBL] [Abstract][Full Text] [Related]
25. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.
Michiels A; Tuyaerts S; Bonehill A; Heirman C; Corthals J; Thielemans K
Methods Mol Biol; 2008; 423():155-63. PubMed ID: 18370196
[TBL] [Abstract][Full Text] [Related]
26. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
27. Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine.
Tateshita N; Miura N; Tanaka H; Masuda T; Ohtsuki S; Tange K; Nakai Y; Yoshioka H; Akita H
J Control Release; 2019 Sep; 310():36-46. PubMed ID: 31386869
[TBL] [Abstract][Full Text] [Related]
28. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
Shemesh CS; Hsu JC; Hosseini I; Shen BQ; Rotte A; Twomey P; Girish S; Wu B
Mol Ther; 2021 Feb; 29(2):555-570. PubMed ID: 33038322
[TBL] [Abstract][Full Text] [Related]
29. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
30. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Miliotou AN; Papadopoulou LC
Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
[TBL] [Abstract][Full Text] [Related]
31. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
Shurin MR; Gregory M; Morris JC; Malyguine AM
Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
[TBL] [Abstract][Full Text] [Related]
32. Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications.
Fucikova J; Palova-Jelinkova L; Bartunkova J; Spisek R
Front Immunol; 2019; 10():2393. PubMed ID: 31736936
[TBL] [Abstract][Full Text] [Related]
33. Programming human dendritic cells with mRNA.
Lee J; Boczkowski D; Nair S
Methods Mol Biol; 2013; 969():111-25. PubMed ID: 23296931
[TBL] [Abstract][Full Text] [Related]
34. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
Goyvaerts C; Breckpot K
J Immunol Res; 2015; 2015():785634. PubMed ID: 26583156
[TBL] [Abstract][Full Text] [Related]
35. Challenges and advances towards the rational design of mRNA vaccines.
Pollard C; De Koker S; Saelens X; Vanham G; Grooten J
Trends Mol Med; 2013 Dec; 19(12):705-13. PubMed ID: 24138818
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
Curran KJ; Pegram HJ; Brentjens RJ
J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
[TBL] [Abstract][Full Text] [Related]
37. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
38. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
39. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
40. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
